TY - JOUR
T1 - Psychological Intervention for Patients with Biopsychosocial Late Effects Following Surgery for Colorectal Cancer with Peritoneal Metastases—A Feasibility Study
AU - Balachandran, Rogini
AU - Thaysen, Henriette Vind
AU - Christensen, Peter
AU - Nissen, Eva Rames
AU - O’Toole, Mia Skytte
AU - Knutzen, Sofie Møgelberg
AU - Buskbjerg, Cecilie Dorthea Rask
AU - Wu, Lisa Maria
AU - Tauber, Nina
AU - Amidi, Ali
AU - Danielsen, Josefine Tingdal Taube
AU - Zachariae, Robert
AU - Iversen, Lene Hjerrild
N1 - Publisher Copyright:
© 2025 by the authors.
PY - 2025/4
Y1 - 2025/4
N2 - Background: Up to 80% of patients experience late effects (LE) one year after surgery for peritoneal metastases (PM) from colorectal cancer (CRC). We tested the feasibility and outcome of a treatment strategy to address LEs. Methods: During January 2021–May 2023, patients who had undergone surgery for CRC-PM in Denmark were screened for biopsychosocial LEs (anxiety, depression, fear of cancer recurrence, insomnia, cognitive impairment, pain, fatigue). Patients scoring according to clinical cut-offs were referred to a Multi-Disciplinary Team conference (MDT). The patients, surgeon(s), nurse(s), and psychologists participated in the MDT, identified key concerns and proposed a personalized intervention. Pre- and post-intervention, patients completed a “Measure Yourself Concerns and Wellbeing” (MYCaW) questionnaire, rating the two most distressing LEs and general wellbeing on a 7-point Likert scale. Results: Of 28 eligible patients, 13 (59 years (mean), 85% women) accepted referral, participated in the MDT, and were offered a personalized intervention. The intervention was completed by 11 patients. Improvement in MYCaW score was observed 1 month postintervention for all three items: (1) the primary LE (p = 0.003, Hedges’s g 1.54), (2) the secondary LE (p < 0.001, Hedges’s g 1.65), and (3) general wellbeing (p = 0.005, Hedges’s g 1.09). This improvement was sustained 6 months postintervention. The 15 non-participants were, in general, older (66 years (mean), men 73%). Conclusions: Screening for LEs and conducting an MDT can provide a personalized intervention plan, which patients are able to complete and may benefit from.
AB - Background: Up to 80% of patients experience late effects (LE) one year after surgery for peritoneal metastases (PM) from colorectal cancer (CRC). We tested the feasibility and outcome of a treatment strategy to address LEs. Methods: During January 2021–May 2023, patients who had undergone surgery for CRC-PM in Denmark were screened for biopsychosocial LEs (anxiety, depression, fear of cancer recurrence, insomnia, cognitive impairment, pain, fatigue). Patients scoring according to clinical cut-offs were referred to a Multi-Disciplinary Team conference (MDT). The patients, surgeon(s), nurse(s), and psychologists participated in the MDT, identified key concerns and proposed a personalized intervention. Pre- and post-intervention, patients completed a “Measure Yourself Concerns and Wellbeing” (MYCaW) questionnaire, rating the two most distressing LEs and general wellbeing on a 7-point Likert scale. Results: Of 28 eligible patients, 13 (59 years (mean), 85% women) accepted referral, participated in the MDT, and were offered a personalized intervention. The intervention was completed by 11 patients. Improvement in MYCaW score was observed 1 month postintervention for all three items: (1) the primary LE (p = 0.003, Hedges’s g 1.54), (2) the secondary LE (p < 0.001, Hedges’s g 1.65), and (3) general wellbeing (p = 0.005, Hedges’s g 1.09). This improvement was sustained 6 months postintervention. The 15 non-participants were, in general, older (66 years (mean), men 73%). Conclusions: Screening for LEs and conducting an MDT can provide a personalized intervention plan, which patients are able to complete and may benefit from.
KW - biopsychosocial
KW - colorectal cancer
KW - late effects
KW - peritoneal metastases
KW - psychological intervention
UR - http://www.scopus.com/inward/record.url?scp=105002370481&partnerID=8YFLogxK
U2 - 10.3390/cancers17071127
DO - 10.3390/cancers17071127
M3 - Journal article
C2 - 40227665
AN - SCOPUS:105002370481
SN - 2072-6694
VL - 17
JO - Cancers
JF - Cancers
IS - 7
M1 - 1127
ER -